Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 2
2014 4
2015 2
2016 1
2017 1
2018 3
2019 3
2020 5
2021 4
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway.
Feng R, Wang X, Chen H, Cao C, Liu T, Zhao T, Chen H, Tian R, Ni Y, Tian X, Hu Z, Ma J, Gong D. Feng R, et al. Curr Cancer Drug Targets. 2023;23(2):159-170. doi: 10.2174/1568009622666220822191039. Curr Cancer Drug Targets. 2023. PMID: 36017858
However, the relationship between PRKD2 and drug resistance of cervical cancer remains unknown. OBJECTIVE: We aim to clarify the relationship between PRKD2 and drug resistance of cervical cancer. ...RESULTS: The expression of PRKD2 was higher in …
However, the relationship between PRKD2 and drug resistance of cervical cancer remains unknown. OBJECTIVE: We aim to clarify t …
HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.
Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T. Azoitei N, et al. Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8. Cancer Res. 2014. PMID: 25297628 Free PMC article.
Here, we report that the oncogenic chaperone HSP90 binds to and stabilizes PRKD2 in human cancer cells. Pharmacologic inhibition of HSP90 with structurally divergent small molecules currently in clinical development triggered proteasome-dependent degradation of P …
Here, we report that the oncogenic chaperone HSP90 binds to and stabilizes PRKD2 in human cancer cells. Pharmacologic inhibiti …
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Walker BA, et al. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Blood. 2018. PMID: 29884741 Free PMC article.
These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and IRF4; t(14;16) with mutations in MAF, BRAF, DIS3, and ATM; and hyperdiploidy with gain 11q, mutations in FAM46C, and MYC rearrangements. ...
These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and I …
The oncogenic role of protein kinase D3 in cancer.
Liu Y, Song H, Zhou Y, Ma X, Xu J, Yu Z, Chen L. Liu Y, et al. J Cancer. 2021 Jan 1;12(3):735-739. doi: 10.7150/jca.50899. eCollection 2021. J Cancer. 2021. PMID: 33403031 Free PMC article. Review.
Protein kinase D3 (PRKD3), a serine/threonine kinase, belongs to protein kinase D family, which contains three members: PRKD1, PRKD2, and PRKD3. PRKD3 is activated by many stimuli including phorbol esters, and G-protein-coupled receptor agonists. PRKD3 promotes cancer …
Protein kinase D3 (PRKD3), a serine/threonine kinase, belongs to protein kinase D family, which contains three members: PRKD1, PRKD2, …
Potential role for protein kinase D inhibitors in prostate cancer.
Chalfant V, Riveros C, Singh P, Shukla S, Balaji N, Balaji KC. Chalfant V, et al. J Mol Med (Berl). 2023 Apr;101(4):341-349. doi: 10.1007/s00109-023-02298-4. Epub 2023 Feb 27. J Mol Med (Berl). 2023. PMID: 36843036 Review.
Protein kinase D (PrKD), a novel serine-threonine kinase, belongs to a family of calcium calmodulin kinases that consists of three isoforms: PrKD1, PrKD2, and PrKD3. The PrKD isoforms play a major role in pathologic processes such as cardiac hypertrophy and cancer p …
Protein kinase D (PrKD), a novel serine-threonine kinase, belongs to a family of calcium calmodulin kinases that consists of three isoforms: …
Rab5c promotes AMAP1-PRKD2 complex formation to enhance beta1 integrin recycling in EGF-induced cancer invasion.
Onodera Y, Nam JM, Hashimoto A, Norman JC, Shirato H, Hashimoto S, Sabe H. Onodera Y, et al. J Cell Biol. 2012 Jun 25;197(7):983-96. doi: 10.1083/jcb.201201065. J Cell Biol. 2012. PMID: 22734003 Free PMC article.
Epidermal growth factor receptor (EGFR) signaling is one of the crucial factors in breast cancer malignancy. Breast cancer cells often overexpress Arf6 and its effector, AMAP1/ASAP1/DDEF1; in these cells, EGFR signaling may activate the Arf6 pathway to induce invasi …
Epidermal growth factor receptor (EGFR) signaling is one of the crucial factors in breast cancer malignancy. Breast cancer cel …
The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y, Wang Y, Yu S, Zhou Y, Ma X, Su Q, An L, Wang F, Shi A, Zhang J, Chen L. Liu Y, et al. Cell Physiol Biochem. 2019;52(3):382-396. doi: 10.33594/000000027. Epub 2019 Mar 8. Cell Physiol Biochem. 2019. PMID: 30845378 Free article.
BACKGROUND/AIMS: Breast cancer is clinically classified into three main subtypes: estrogen receptor-positive (ER(+)) breast cancer, human epidermal growth factor receptor 2-positive (HER2(+)) breast cancer, and triple-negative breast cancer (TNBC). ... …
BACKGROUND/AIMS: Breast cancer is clinically classified into three main subtypes: estrogen receptor-positive (ER(+)) breast cancer …
Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX.
Horikawa M, Sabe H, Onodera Y. Horikawa M, et al. Transl Oncol. 2022 Jan;15(1):101258. doi: 10.1016/j.tranon.2021.101258. Epub 2021 Nov 3. Transl Oncol. 2022. PMID: 34742153 Free PMC article.
However, mechanisms of CAIX trafficking, which affects such CAIX-targeting modalities remain unclear. In this study, roles of the AMAP1-PRKD2 pathway, which mediates integrin recycling of invasive cancer cells, in CAIX trafficking were investigated. ...High-ASAP1 (A …
However, mechanisms of CAIX trafficking, which affects such CAIX-targeting modalities remain unclear. In this study, roles of the AMAP1-P …
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ. Ou O, et al. Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1. Cancer Lett. 2014. PMID: 25193464 Free PMC article.
Targeting of the PI3K/AKT/mTOR pathway through inhibition of mTOR in combination with aromatase inhibitors has seen success in particular sub-types of breast cancer and there is a need to identify additional synergistic combinations to maximize the clinical potential of mT …
Targeting of the PI3K/AKT/mTOR pathway through inhibition of mTOR in combination with aromatase inhibitors has seen success in particular su …
Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland.
Piscuoglio S, Fusco N, Ng CK, Martelotto LG, da Cruz Paula A, Katabi N, Rubin BP, Skálová A, Weinreb I, Weigelt B, Reis-Filho JS. Piscuoglio S, et al. Histopathology. 2016 Jun;68(7):1055-62. doi: 10.1111/his.12883. Epub 2016 Jan 4. Histopathology. 2016. PMID: 26426580 Free PMC article.
The vast majority of PLGAs harbour a PRKD1 E710D hot-spot somatic mutation or somatic rearrangements of PRKD1, PRKD2 or PRKD3. Given the kinase domain homology among PRKD1, PRKD2 and PRKD3, we sought to define whether PLGAs lacking PRKD1 somatic mutations or PRKD ge …
The vast majority of PLGAs harbour a PRKD1 E710D hot-spot somatic mutation or somatic rearrangements of PRKD1, PRKD2 or PRKD3. Given …
32 results